Johnson & Johnson (NYSE:JNJ) updated its FY19 earnings guidance on Tuesday. The company provided earnings per share guidance of $8.53-8.63 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.59. The company issued revenue guidance of $80.4-81.2 billion, compared to the consensus revenue estimate of $81.17 billion.Johnson & Johnson also updated its FY 2019 guidance to $8.53-8.63 EPS.
JNJ traded down $0.18 during trading on Wednesday, hitting $139.79. 4,110,995 shares of the stock traded hands, compared to its average volume of 6,738,609. The company has a quick ratio of 1.13, a current ratio of 1.44 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $381.21 billion, a P/E ratio of 17.09, a PEG ratio of 2.46 and a beta of 0.67. Johnson & Johnson has a 12-month low of $118.62 and a 12-month high of $148.99.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 16th. The company reported $2.10 earnings per share for the quarter, beating analysts’ consensus estimates of $2.03 by $0.07. Johnson & Johnson had a net margin of 17.99% and a return on equity of 36.29%. The business had revenue of $20.02 billion during the quarter, compared to analyst estimates of $19.55 billion. During the same period last year, the business earned $2.06 EPS. Johnson & Johnson’s revenue was up .1% compared to the same quarter last year. Sell-side analysts expect that Johnson & Johnson will post 8.6 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 11th. Investors of record on Tuesday, May 28th will be issued a $0.95 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.90. The ex-dividend date is Friday, May 24th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.72%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 44.01%.
A number of equities analysts recently issued reports on JNJ shares. Zacks Investment Research downgraded shares of Johnson & Johnson from a hold rating to a sell rating in a report on Tuesday, January 8th. Wells Fargo & Co reaffirmed an outperform rating and set a $152.00 price target (down previously from $162.00) on shares of Johnson & Johnson in a report on Monday, January 14th. Barclays reaffirmed an equal weight rating and set a $135.00 price target (down previously from $137.00) on shares of Johnson & Johnson in a report on Wednesday, January 23rd. Citigroup lifted their price objective on shares of Johnson & Johnson from $139.00 to $147.00 and gave the company a neutral rating in a research report on Monday, February 25th. Finally, Raymond James lifted their price objective on shares of Johnson & Johnson from $145.00 to $147.00 and gave the company an outperform rating in a research report on Wednesday, April 17th. Five research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average target price of $146.90.
Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. increased its holdings in shares of Johnson & Johnson by 1.9% during the fourth quarter. BlackRock Inc. now owns 182,903,344 shares of the company’s stock valued at $23,603,679,000 after acquiring an additional 3,486,924 shares in the last quarter. Oregon Public Employees Retirement Fund increased its holdings in Johnson & Johnson by 11,576.1% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 74,757,633 shares of the company’s stock worth $579,000 after buying an additional 74,117,373 shares during the period. Geode Capital Management LLC increased its holdings in Johnson & Johnson by 8.2% in the 4th quarter. Geode Capital Management LLC now owns 36,364,874 shares of the company’s stock worth $4,685,372,000 after buying an additional 2,741,351 shares during the period. Northern Trust Corp increased its holdings in Johnson & Johnson by 3.6% in the 4th quarter. Northern Trust Corp now owns 34,815,401 shares of the company’s stock worth $4,492,928,000 after buying an additional 1,202,514 shares during the period. Finally, Legal & General Group Plc boosted its position in Johnson & Johnson by 5.5% in the 4th quarter. Legal & General Group Plc now owns 13,534,538 shares of the company’s stock worth $1,746,552,000 after purchasing an additional 710,059 shares in the last quarter. 67.20% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: Diversification in Investing